Previous Close | 63.29 |
Open | 64.94 |
Bid | 63.55 |
Ask | 64.85 |
Strike | 45.00 |
Expire Date | 2024-09-20 |
Day's Range | 61.30 - 64.94 |
Contract Range | N/A |
Volume | |
Open Interest | 3 |
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.